busulfan has been researched along with Lymphoproliferative Disorders in 10 studies
Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cyclosporin A and short methotrexate were used for graft-versus-host disease (GVHD) prophylaxis." | 5.08 | Combined transplantation of allogeneic bone marrow and CD34+ blood cells. ( Arseniev, L; Bähre, O; Battmer, K; Berenson, RJ; Casper, J; Diedrich, H; Jacobs, R; Kadar, JG; Kühl, J; Link, H; Poliwoda, H; Schubert, J, 1995) |
| "One hundred two patients (Hodgkin lymphoma n = 49, non-Hodgkin lymphoma n = 12, multiple myeloma = 41) with a median age of 44 years (range: 19-65 years) were treated." | 2.76 | Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. ( Andersson, BS; Champlin, RE; Hosing, C; Jones, RB; Kazerooni, R; Kebriaei, P; Khouri, I; Ledesma, C; Madden, T; Nieto, Y; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Rafferty, C | 1 |
| Velangi, M | 1 |
| Lawson, S | 1 |
| Hiwarkar, P | 1 |
| Motwani, J | 1 |
| Marinho-Dias, J | 1 |
| Lobo, J | 1 |
| Henrique, R | 1 |
| Baldaque, I | 1 |
| Pinho-Vaz, C | 1 |
| Regadas, L | 1 |
| Branca, R | 1 |
| Campilho, F | 1 |
| Campos, A | 1 |
| Medeiros, R | 1 |
| Sousa, H | 1 |
| Luo, L | 1 |
| Zhang, L | 1 |
| Cai, B | 1 |
| Li, H | 1 |
| Huang, W | 1 |
| Jing, Y | 1 |
| Zhu, H | 1 |
| Zhao, Y | 1 |
| Bo, J | 1 |
| Wang, Q | 1 |
| Han, X | 1 |
| Yu, L | 1 |
| Gao, C | 1 |
| Kebriaei, P | 1 |
| Madden, T | 1 |
| Kazerooni, R | 1 |
| Wang, X | 1 |
| Thall, PF | 1 |
| Ledesma, C | 1 |
| Nieto, Y | 1 |
| Shpall, EJ | 1 |
| Hosing, C | 1 |
| Qazilbash, M | 1 |
| Popat, U | 1 |
| Khouri, I | 1 |
| Champlin, RE | 1 |
| Jones, RB | 1 |
| Andersson, BS | 1 |
| Kusumi, E | 1 |
| Taniguchi, S | 1 |
| Kiefer, T | 1 |
| Krüger, WH | 1 |
| Schüler, F | 1 |
| Lotze, C | 1 |
| Hirt, C | 1 |
| Dölken, G | 1 |
| Zhu, KE | 1 |
| Li, JP | 1 |
| Zhang, T | 1 |
| Zhong, J | 1 |
| Chen, J | 1 |
| Link, H | 1 |
| Arseniev, L | 1 |
| Bähre, O | 1 |
| Berenson, RJ | 1 |
| Battmer, K | 1 |
| Kadar, JG | 1 |
| Jacobs, R | 1 |
| Casper, J | 1 |
| Kühl, J | 1 |
| Schubert, J | 1 |
| Diedrich, H | 1 |
| Poliwoda, H | 1 |
| Schmitz, N | 1 |
| Bacigalupo, A | 1 |
| Labopin, M | 1 |
| Majolino, I | 1 |
| Laporte, JP | 1 |
| Brinch, L | 1 |
| Cook, G | 1 |
| Lambertenghi-Deliliers, G | 1 |
| Lange, A | 1 |
| Rozman, C | 1 |
| Garcia-Conde, J | 1 |
| Finke, J | 1 |
| Domingo-Albos, A | 1 |
| Gratwohl, A | 1 |
| Corvò, R | 1 |
2 reviews available for busulfan and Lymphoproliferative Disorders
| Article | Year |
|---|---|
[Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases].
Topics: Busulfan; Cause of Death; Clinical Trials as Topic; Disease-Free Survival; Graft vs Host Disease; He | 2003 |
[Total body irradiation in hematology: clinical indications and prospects].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
2 trials available for busulfan and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu | 2011 |
Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclos | 1995 |
6 other studies available for busulfan and Lymphoproliferative Disorders
| Article | Year |
|---|---|
IFNɣ Block, Treosulfan Conditioning and αβ T Cell Deplete PBSCT for XIAP-Deficient HLH.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antigens, CD19; Busulfan; Chimerism; Genetic Diseases, | 2017 |
Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Epstein-Barr Virus Infection | 2018 |
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child; Child, Presch | 2014 |
The modification of high-dose therapy shortens the duration of neutropaenia by delay of leucocyte nadir.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Infec | 2006 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antig | 2007 |
Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience.
Topics: Adolescent; Adult; Blood Donors; Busulfan; Child; Child, Preschool; Cyclosporine; Erythropoietin; Fe | 1996 |